This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency (VITAPID)

This study has been completed.
Information provided by (Responsible Party):
Peter Bergman, Karolinska University Hospital Identifier:
First received: May 26, 2010
Last updated: April 4, 2012
Last verified: April 2012
Hypothesis: Cholecalciferol (vitamin D3) prevent respiratory tract infections in patients with primary immunodeficiency.

Condition Intervention Phase
Primary Immune Deficiency Disorder Drug: Vigantol Drug: Placebo Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Placebo Controlled Double Blinded Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency

Resource links provided by NLM:

Further study details as provided by Peter Bergman, Karolinska University Hospital:

Primary Outcome Measures:
  • Infectious score [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Antimicrobial peptide expression in nasal fluid [ Time Frame: 12 months ]
  • Serum levels of 25-OH Vitamin D3 [ Time Frame: 12 months ]
  • Consumption of antibiotics [ Time Frame: 12 months ]
  • Number of positive bacterial cultures in nasal swabs [ Time Frame: 12 months ]

Enrollment: 140
Study Start Date: March 2010
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Drug: Placebo
Active Comparator: Vitamin D
Vigantol (cholecalciferol) 4000 IE/day
Drug: Vigantol
Vigantol 4000IU/day


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18-75
  • Increased number of respiratory tract infections
  • At least 42 days of infections during 2008 or 2009
  • S-25 OH vitamin D3 < 250 nM
  • Not planning a pregnancy during the coming year
  • Accepting the use of contraceptives during 1 year

Exclusion Criteria:

  • Continuous antibiotic treatment
  • Hypercalcemia
  • Sarcoidosis
  • Kidney disease
  • Tuberculosis
  • Pregnancy
  • Kidney stone
  • Heart medication (glycosides)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01131858

Karolinska Univerisity Hospital
Stockholm, Sweden, 18146
Sponsors and Collaborators
Karolinska University Hospital
Principal Investigator: Jan Andersson, MD/PhD Karolinska University Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Peter Bergman, MD, PhD, Karolinska University Hospital Identifier: NCT01131858     History of Changes
Other Study ID Numbers: 2009/1678-31/4
Study First Received: May 26, 2010
Last Updated: April 4, 2012

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Immune System Diseases
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on September 21, 2017